ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
ITeos Therapeutics Has Dosed First Patient In GALAXIES Lung-301 Phase 3 Trial Of Belrestotug+Dostarlimab Vs. Placebo+Pembrolizumab For First-line Advanced, Unresectable, Or Metastatic PD-L1 High Non-Small Cell Lung Cancer
This event has triggered $35 million in development milestone payments from GSK, its partner for belrestotug.
这一事件已经触发了全球货币3500万的开发阶段支付，这是其合作伙伴GSk为belrestotug所支付的。
iTeos and GSK entered into an exclusive development and commercialization collaboration in June 2021 for belrestotug, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations. Per the agreement, iTeos received a $625 million upfront payment from GSK with development and regulatory milestones up to $550 million and commercial milestones up to $900 million. In addition to the milestones, GSK and iTeos will jointly commercialize and equally split profits in the US. Outside the US, GSK will receive an exclusive license for commercialization and iTeos will receive tiered royalty payments. Within the collaboration, GSK and iTeos share responsibility and costs for the global development of belrestotug.
iTeos和GSk于2021年6月签署了一项独家开发和商业化合作协议，旨在合作开发抗TIGIt单克隆抗体belrestotug，以实现创新的下一代免疫治疗组合。根据协议，iTeos从GSk获得了62500万美元的预付款，并获得了高达55000万美元的开发和监管里程碑以及高达90000万美元的商业里程碑。除了里程碑外，GSk和iTeos在美国共同商业化并平分利润。在美国以外地区，GSk将获得商业化的独家许可，iTeos将获得分层版税支付。在合作中，GSk和iTeos共同承担全球货币的开发责任和成本。